CAMBRIDGE, Mass., July 11,
2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
(Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for
severe neurodegenerative diseases, today announced it will
participate in two upcoming conferences that aim to advance
treatments and solutions to improve the lives of people living with
amyotrophic lateral sclerosis (ALS).
European Network to Cure ALS (ENCALS)
July 12-14, 2023
Barcelona, Spain
NeuroSense's Chief Medical Officer, Dr. Ferenc Tracik, and VP of R&D, Dr. Shiran
Zimri, will participate in the ENCALS conference where researchers,
academics, and professionals from around the world gather to share
knowledge, ideas, and advancements in their respective ALS
fields. NeuroSense aims to create new partnerships at ENCALS,
while strengthening our existing connections with the European ALS
scientific community.
EverythingALS Digital Biomarkers Summit
July 23-24, 2023
Boston, Massachusetts, USA
NeuroSense's CEO, Alon Ben-Noon,
VP of BD, Nedira Salzman-Frenkel, and Dr. Zimri, will participate
in the EverythingALS Digital Biomarkers Summit: A Meeting of the
Minds in ALS. This invitation-only collaboration event for
EverythingALS Consortia members aims to share insights, prioritize,
and commit to moving the needle on biomarker and clinical trial end
point development for ALS via focused workshops with renowned key
opinion leaders. EverythingALS is a patient-focused non-profit
bringing technological innovations and data science to support
efforts, from care to cure, for people with ALS by offering an
open-data platform for direct engagement with patients, caregivers,
researchers, and drug companies.
"NeuroSense is committed to working in collaboration with the
leading minds and organizations on the forefront of advancing
toward effective treatments for ALS and to improve the lives of
those living with ALS and their families. We look forward to
participating in these important upcoming conferences," stated
Alon Ben-Noon, CEO of
NeuroSense.
About NeuroSense
NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology
company focused on discovering and developing treatments for
patients suffering from debilitating neurodegenerative diseases.
NeuroSense believes that these diseases, which include amyotrophic
lateral sclerosis (ALS), Alzheimer's disease and Parkinson's
disease, among others, represent one of the most significant unmet
medical needs of our time, with limited effective therapeutic
options available for patients to date. Due to the complexity of
neurodegenerative diseases and based on strong scientific research
on a large panel of related biomarkers, NeuroSense's strategy is to
develop combined therapies targeting multiple pathways associated
with these diseases.
For additional information, we invite you to visit
our website and follow us
on LinkedIn and Twitter.
Forward-Looking Statements
This press release contains "forward-looking statements" that
are subject to substantial risks and uncertainties. All statements,
other than statements of historical fact, contained in this press
release are forward-looking statements. Forward-looking statements
contained in this press release may be identified by the use of
words such as "anticipate," "believe," "contemplate," "could,"
"estimate," "expect," "intend," "seek," "may," "might," "plan,"
"potential," "predict," "project," "target," "aim," "should,"
"will" "would," or the negative of these words or other similar
expressions, although not all forward-looking statements contain
these words. Forward-looking statements are based on NeuroSense
Therapeutics' current expectations and are subject to inherent
uncertainties, risks and assumptions that are difficult to predict
and include statements regarding the creation of new partnerships
at ENCALS. Further, certain forward-looking statements are based on
assumptions as to future events that may not prove to be accurate.
Forward-looking statements are subject to a number of risks and
uncertainties, including inability to create new partnerships and
delays in clinical and regulatory milestones. The future events and
trends may not occur and actual results could differ materially and
adversely from those anticipated or implied in the forward looking
statements. You should not rely on these statements as representing
our views in the future. More information about the risks and
uncertainties affecting the Company is contained under the heading
"Risk Factors" in the Annual Report on Form 20-F filed with the
Securities and Exchange Commission on March
22, 2023. Forward-looking statements contained in this
announcement are made as of this date, and NeuroSense Therapeutics
Ltd. undertakes no duty to update such information except as
required under applicable law.
Logo -
https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/neurosense-to-participate-in-upcoming-als-conferences-european-network-to-cure-als--everythingals-digital-biomarkers-summit-301874165.html
SOURCE NeuroSense